Lenalidomide Should NOT Be Routinely Held for Active Infection
Lenalidomide does not need to be held during active infection; instead, infections should be treated aggressively with broad-spectrum antibiotics while continuing myeloma therapy, with prophylactic antibiotics recommended during the first 3 months of lenalidomide treatment. 1
Management Algorithm for Infections During Lenalidomide Therapy
Active Infection Management
- Immediate broad-spectrum antibiotic therapy is the priority when infection occurs 1
- Continue lenalidomide unless there are specific contraindications (severe neutropenia with active sepsis, life-threatening infection requiring ICU-level care)
- Monitor for neutropenia and use G-CSF if grade 3/4 neutropenia develops 2
Prophylaxis Strategy (Critical to Prevent Infections)
The most recent EHA-EMN guidelines (2025) provide clear direction on infection prevention rather than drug interruption:
Mandatory prophylaxis during lenalidomide therapy:
- Prophylactic antibiotics (levofloxacin) for the first 3 months of therapy, especially in patients receiving lenalidomide or those at high risk 1
- Sulfamethoxazole-trimethoprim for Pneumocystis jirovecii prevention 1
- Acyclovir or valacyclovir for herpes zoster prophylaxis if combined with proteasome inhibitors or anti-CD38 antibodies 1
Evidence Supporting Continuation During Infection
The guideline evidence emphasizes treating infections aggressively rather than holding antimyeloma therapy 1. This approach prioritizes:
- Morbidity/Mortality: Stopping effective myeloma therapy risks disease progression, which itself increases infection risk due to immune compromise from active myeloma
- Quality of Life: Maintaining disease control prevents myeloma-related complications
Research data confirms lenalidomide increases infection risk (14.32% high-grade infections, RR 2.23) 3, but this is managed through prophylaxis and prompt treatment, not drug discontinuation. Real-world data shows only 5.5% grade 3 bacterial infections with RVd despite low prophylaxis use 4, suggesting infections are manageable without routine drug holds.
When to Consider Holding Lenalidomide
Specific scenarios warranting temporary hold:
- Grade 4 neutropenia (<500/μL) with active sepsis or febrile neutropenia
- Life-threatening infection requiring ICU admission
- Infection not responding to appropriate antibiotics after 48-72 hours with concurrent severe neutropenia
Resume lenalidomide when:
- Infection controlled with antibiotics
- Neutrophil count recovering (>500/μL trending upward)
- Patient clinically stable
Common Pitfalls to Avoid
- Do not reflexively hold lenalidomide for uncomplicated infections (pneumonia, UTI, cellulitis) that respond to antibiotics
- Do not wait for infection to completely resolve before restarting if neutrophil counts permit
- Do not forget prophylaxis - the 3-month prophylactic antibiotic window is evidence-based and prevents most serious infections 1
- Consider G-CSF prophylaxis in patients with recurrent neutropenia rather than repeated dose reductions 2
The paradigm has shifted from reactive drug holds to proactive infection prevention while maintaining effective antimyeloma therapy to optimize survival outcomes.